<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03026556</url>
  </required_header>
  <id_info>
    <org_study_id>1160-0274</org_study_id>
    <nct_id>NCT03026556</nct_id>
  </id_info>
  <brief_title>The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis</brief_title>
  <official_title>Safety and Effectiveness Study Comparing Dabigatran, Rivaroxaban &amp; Apixaban in Non-valvular Atrial Fibrillation Patients Enrolled in the US Department of Defense Military Health System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health ResearchTx, LLC (HRTX)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>inVentiv Health Clinical (iVH)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense (DOD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of newly initiated
      dabigatran among patients diagnosed with non valvular atrial fibrillation (NVAF) in
      comparison to newly initiated rivaroxaban users and newly initiated apixaban users
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 29, 2016</start_date>
  <completion_date type="Actual">August 23, 2017</completion_date>
  <primary_completion_date type="Actual">August 23, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stroke Overall (hemorrhagic, ischemic, uncertain)</measure>
    <time_frame>6 years</time_frame>
    <description>Stroke Overall (hemorrhagic, ischemic, uncertain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>6 years</time_frame>
    <description>Ischemic stroke</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">35130</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Dabigatran vs. Rivaroxaban</arm_group_label>
    <description>OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, rivaroxaban (new oral anticoagulant or NOAC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran vs. Apixaban</arm_group_label>
    <description>OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, or apixaban (new oral anticoagulant or NOAC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran vs. Rivaroxaban</intervention_name>
    <description>observed for 6 years</description>
    <arm_group_label>Dabigatran vs. Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran vs. Apixaban</intervention_name>
    <description>Observed for 6 years</description>
    <arm_group_label>Dabigatran vs. Apixaban</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        NVAF patients, ≥18 years of age, enrolled within the DoD Military Health System, who have
        newly initiated dabigatran, rivaroxaban, or apixaban. Patients must be treatment naïve from
        OAC use prior to first (index) NOAC.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18+ on index date

          -  Patients must have been prescribed either dabigatran, rivaroxaban, or apixaban
             identified by pharmacy claim during the study period. The first dispensing date of
             either study drug will be defined as the index date;

          -  Patients must be treatment naïve from all OAC use prior to the first NOAC
             prescription, during study period.

          -  Patients must have at least 12 months of continuous eligibility prior to the index
             date; -Patients must have at least one diagnosis code of atrial fibrillation, defined
             as ICD- 9-CM diagnosis of 427.31 or ICD-10-CM diagnosis of I48.0, I48.1, I48.2, I48.91
             on the index date or during the pre-index period.

        Exclusion Criteria:

        Less than 12 months of continuous eligibility in the pre-index period Any claim for OAC
        drug (oral use only) in the pre-index period Diagnosis of hyperthyroidism during the
        pre-index period Having at least one claim for alternative indications; orthopedic
        procedures, VTE (includes DVT &amp;PE) and the index NOAC prescription at the same time, or,
        the alternative indication for anticoagulant occurring within 3 months prior to index date
        in pre-period Having at least one claim with any of the following diagnoses or procedure
        codes in order to exclude patients with &quot;transient&quot; causes of Afib (3 months prior to index
        date in pre-period):

          -  Cardiac surgery

          -  Pericarditis

          -  Myocarditis Having at least one medical claim with any of the following diagnoses or
             procedures codes in order to exclude patients with &quot;valvular&quot; Afib (pre-period):

          -  Mitral stenosis

          -  Mitral stenosis with insufficiency

          -  Mitral valve stenosis and aortic valve stenosis

          -  Mitral valve stenosis and aortic valve insufficiency

          -  Diseases of other endocardial structures

          -  Other and unspecified rheumatic heart diseases

          -  Open heart valvuloplasty without replacement

          -  Open and other replacement of unspecified heart valve

          -  Open and other replacement of aortic valve

          -  Open and other replacement of mitral valve

          -  Open and other replacement of pulmonary valve

          -  Open and other replacement of tricuspid valve

          -  Heart valve replaced by transplant

          -  Heart valve replaced by a mechanical device/prosthesis

          -  Atrioventricular valve repair

          -  Aortic valve valvuloplasty

          -  Unlisted procedure, cardiac surgery

          -  Implantation of catheter-delivered prosthetic aortic heart valve; open thoracic
             approach

          -  Transthoracic cardiac exposure (e.g., sternotomy, thoracotomy, subxiphoid) for
             catheter-delivered aortic valve replacement; without cardiopulmonary bypass

          -  Transthoracic cardiac exposure (e.g., sternotomy, thoracotomy, subxiphoid) for
             catheter-delivered aortic valve replacement; with cardiopulmonary bypass

          -  Replacement, aortic valve, with cardiopulmonary bypass; with prosthetic valve other
             than homograft or stentless valve

          -  Valvuloplasty, mitral valve, with cardiopulmonary bypass

          -  Valvuloplasty, mitral valve, with cardiopulmonary bypass; with prosthetic ring

          -  Valvuloplasty, mitral valve, with cardiopulmonary bypass; radical reconstruction, with
             or without ring

          -  Replacement, mitral valve, with cardiopulmonary bypass

          -  Implantation of catheter-delivered prosthetic pulmonary valve, endovascular approach

          -  Replacement, pulmonary valve

          -  Valvectomy, tricuspid valve, with cardiopulmonary bypass

          -  Valvuloplasty, tricuspid valve; without ring insertion

          -  Valvuloplasty, tricuspid valve; with ring insertion

          -  Replacement, tricuspid valve, with cardiopulmonary bypass
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inventiv Health</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2017</study_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

